Mesenchymal stem cells in hematology: therapeutic initiatives and future directions

Best Practice & Research Clinical Haematology, Год журнала: 2025, Номер unknown, С. 101613 - 101613

Опубликована: Март 1, 2025

Язык: Английский

---

Lack of IFN-γ response of human uterine myometrium-derived MSCs significantly improve multiple IBD parameters compared to bone marrow MSCs: implications for anti-TNFα-refractory patients

Pharmacological Research, Год журнала: 2025, Номер unknown, С. 107716 - 107716

Опубликована: Март 1, 2025

Язык: Английский

---

Cisplatin-Mediated IL-6 and IDO1 Suppression in Mesenchymal Stromal Cells: Implications for Tumor Microenvironment Modulation In Vitro

Current Issues in Molecular Biology, Год журнала: 2025, Номер 47(4), С. 231 - 231

Опубликована: Март 27, 2025

Mesenchymal stromal cells (MSCs) influence tumor biology and immunology by releasing cytokines, chemokines growth factors. Currently, cisplatin is an integral part of drug-based therapy, for example, in head neck squamous cell carcinoma (HNSCC). Cisplatin treatment induces apoptosis as a primary mechanism action; however, additional immunomodulatory effects are gaining interest. The aim this study to evaluate the possible human MSCs (hMSCs). MSCs, obtained from bone marrow, were characterized analyzing plastic adherence, typical surface features, ability differentiate. Toxicity analysis cisplatin’s on including determination subtoxic concentration, was performed using MTT assay. Enzyme-linked immunosorbent assays (ELISA) quantitative real-time polymerase chain reaction (qRT-PCR) used identify potentially Additionally, scratch assay migration. First, concentrations determined. A significantly reduced protein expression indoleamine 2,3-dioxygenase 1 (IDO1) under demonstrated. Similarly, IL-6 qualitatively at concentrations, although without statistical significance. At mRNA level, qRT-PCR showed non-significant, concentration-dependent reduction both IDO1. no statistically significant migration after treatment. In there tendency decrease IDO1 level exposure. These congruent with each other dose-dependent. This indicates that not only acts via known cytotoxic effect, but may induce tumor-supporting proteins, like IDO1, microenvironment concentrations. Traditional cytostatic compounds, which can favorably modulate immune system microenvironment, open new avenues explore strategies specifically targeting immunomodulation. Overall, results indicate beneficial immunomodulation cisplatin.

Язык: Английский

---

Cell-based Therapies for Acute Respiratory Distress Syndrome: Where Are We Now?

American Journal of Respiratory and Critical Care Medicine, Год журнала: 2024, Номер 209(7), С. 789 - 797

Опубликована: Фев. 7, 2024

Section:ChooseTop of pageAbstract <

Язык: Английский

---

Biology and Therapeutic Properties of Mesenchymal Stem Cells in Leukemia

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(5), С. 2527 - 2527

Опубликована: Фев. 21, 2024

This comprehensive review delves into the multifaceted roles of mesenchymal stem cells (MSCs) in leukemia, focusing on their interactions within bone marrow microenvironment and impact leukemia pathogenesis, progression, treatment resistance. MSCs, characterized by ability to differentiate various cell types modulate immune system, are integral BM niche, influencing hematopoietic maintenance functionality. extensively explores intricate relationship between MSCs leukemic acute myeloid lymphoblastic chronic lymphocytic leukemia. also addresses potential clinical applications treatment. MSCs’ role transplantation, antitumor effects, strategies disrupt chemo-resistance discussed. Despite therapeutic potential, dual nature promoting inhibiting tumor growth poses significant challenges. Further research is needed understand biological mechanisms hematologic malignancies develop targeted strategies. in-depth exploration provides crucial insights for advancing modalities improving patient outcomes malignancies.

Язык: Английский

---

Proteomic analysis and functional validation reveal distinct therapeutic capabilities related to priming of mesenchymal stromal/stem cells with IFN-γ and hypoxia: potential implications for their clinical use

Frontiers in Cell and Developmental Biology, Год журнала: 2024, Номер 12

Опубликована: Май 31, 2024

Mesenchymal stromal/stem cells (MSCs) are a heterogeneous population of multipotent that can be obtained from various tissues, such as dental pulp, adipose tissue, bone marrow and placenta. MSCs have gained importance in the field regenerative medicine because their promising role cell therapy regulatory abilities tissue repair regeneration. However, better characterization these products is necessary to further potentiate clinical application. In this study, we used unbiased high-resolution mass spectrometry-based proteomic analysis investigate impact distinct priming strategies, hypoxia IFN-γ treatment, on composition therapeutic functionality secretome produced by derived amniotic membrane human placenta (hAMSCs). Our investigation revealed both types improved efficacy hAMSCs, improvements were related secretion functional factors present conditioned medium (CM) exosomes (EXOs), which play crucial roles mediating paracrine effects MSCs. particular, was able induce pro-angiogenic, innate immune response-activating, tissue-regenerative hAMSC phenotype, highlighted elevated production VEGFA, PDGFRB, ANGPTL4, ENG, GRO-γ, IL8, GRO-α. priming, instead, led an immunosuppressive profile indicated increased levels TGFB1, ANXA1, THBS1, HOMER2, GRN, TOLLIP MCP-1. Functional assays validated angiogenic properties hypoxic hAMSCs enhanced activity IFN-γ-treated hAMSCs. This study extends beyond direct demonstrating influence characteristics hAMSC-derived secretomes, which, turn, orchestrate peripheral blood cells. research provides valuable insights into optimization MSC-based therapies systematically assessing comparing type-specific features These findings highlight new strategies for enhancing MSCs, particularly context multifactorial diseases, paving way use practice.

Язык: Английский

---

Advancements in graft-versus-host disease prevention in hematopoietic stem cell transplantation

Iraqi Journal of Hematology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 8, 2025

Abstract: Graft-versus-host disease (GVHD) remains a critical obstacle in the success of allogeneic hematopoietic stem cell transplantation (HSCT), adversely affecting patient survival and posttransplant quality life. Recent advancements GVHD prophylaxis emphasize achieving delicate equilibrium between effective immunosuppression preservation graft-versus-tumor (GVT) effect. This article synthesizes cutting-edge developments, including immune modulation strategies such as regulatory T-cell expansion cytokine blockade, novel pharmacological approaches like Janus kinase inhibitors cyclophosphamide, cellular therapies leveraging mesenchymal stromal cells ex vivo-expanded T cells. Furthermore, advent biomarkers ST2 microRNA signatures has enabled early risk stratification, fostering personalized, risk-adapted prophylactic strategies. By integrating these innovations, HSCT outcomes can be significantly improved, offering enhanced safety, reduced incidence, optimized long-term care.

Язык: Английский

---

Inhibition of TGF-β signaling enhances osteogenic potential of iPSC-derived MSCs

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Март 6, 2025

Mesenchymal stem cells (MSCs) represent the most commonly utilized type of cell in clinical applications. However, variability quality and quantity between different tissue sources donors presents a significant challenge to their use. Induced pluripotent (iPSCs) are promising abundant alternative source MSCs, offering potential solution limitations adult MSCs. Nevertheless, standardized protocol for differentiation iPSCs into iPSC-derived mesenchymal (iMSCs) has yet be established, as existing methods vary significantly terms complexity, duration, outcome. Many straightforward induce by culturing MSC media which supplemented with fetal bovine serum (FBS) or human platelet lysate (hPL), followed selection MSC-like passaging. our hands, this approach yielded inconsistent iMSCs, particularly osteogenic premature senescence. This study examines impact selective TGF-β inhibitor SB431542 on iMSC differentiation, demonstrating that inhibition enhances reduces Additionally, we present reliable, xeno-free method producing high-quality iMSCs can adapted Good Manufacturing Practice (GMP) compliance, thus enhancing

Язык: Английский

---

Clinical and molecular landscapes of steroid-refractory graft-versus-host disease following hematopoietic stem cell transplantation: a narrative review

Regenerative medicine reports ., Год журнала: 2025, Номер 2(2), С. 53 - 60

Опубликована: Апрель 8, 2025

Allogeneic hematopoietic stem cell transplantation is a highly effective cell-based therapy, but graft-versus-host disease remains major post-transplant complication. While first-line treatment involves high-dose corticosteroids, up to half of patients go on develop steroid-refractory disease, where symptoms persist or worsen despite steroid treatment. This review provides an update the clinical and molecular landscapes examining challenges in diagnosis, management, general understanding pathophysiology. Progression confers poor prognosis associated with increased morbidity. There are multiple mechanisms that drive which include overactivation T-cell B-cell mechanisms, heightened inflammatory state, cell-intrinsic factors mediate responses. Current options beyond corticosteroids JAK pathway inhibition, mesenchymal extracorporeal photopheresis, additional therapies currently under investigation trials. Potential avenues for future directions must aim improve patient outcomes survivorship. Through comprehensive elucidation underlying development mechanism-based, regenerative medicine-targeted therapeutic strategies, optimization trial design, it anticipated quality life will be significantly improved. From standpoint, these advancements expected catalyze transition from empirical more personalized, mechanism-directed therapies, ultimately providing durable disease.

Язык: Английский

---

Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation: An Open-Label, Multicenter, Randomized Controlled Clinical Trial

Journal of Clinical Oncology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 15, 2025

PURPOSE The aim of this open-label, multicenter, randomized controlled trial was to determine the efficacy and safety sequential umbilical cord–derived mesenchymal stem cell (UC-MSC) infusion for graft-versus-host disease (GVHD) prevention within 3 months haploidentical hematopoietic transplantation (haplo-HSCT). METHODS This open-label study evaluated UC-MSC (administer 1 × 10 6 /kg 4 hours before commencement day 0, once weekly first month after transplantation, every 2 weeks second month, during third totaling eight doses). primary end point 2-year cumulative incidence severe chronic GVHD (cGVHD). RESULTS In analysis, 192 qualified participants between age 18 60 years with haplo-HSCT in three transplant centers China were enrolled randomly assigned MSC control groups. estimated cGVHD all grades lower group than ( P = .033 .022). grade 4, acute (aGVHD) patients significantly decreased (all < .001). 3-year GVHD-free relapse-free survival (GRFS) rate 62.4%, which higher that (32.0%, hazard ratio [HR], 0.34, did not influence relapse .34) nonrelapse mortality .45). CONCLUSION Our findings suggest MSCs reduced both severity aGVHD, manifesting as a better GRFS patients.

Язык: Английский

---